CIK 0000315545 · Non-accelerated filer<br>Smaller reporting company
PROVECTUS BIOPHARMACEUTICALS, INC.
Sign in to watch- Ticker
- PVCT
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 900031917
- Phone
- (866) 594-5999
- Business address
- 800 S. GAY STREET, SUITE 1610, KNOXVILLE, TN, 37929
- Former names
- PROVECTUS PHARMACEUTICALS INC, PROVECTUS PHARMACEUTICAL INC, ZAMAGE DIGITAL IMAGING INC, SPM GROUP INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-20 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2025-02-27 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2025-02-27 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +67,953 | 1,895,576 | ||
| 2025-02-20 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2025-02-15 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2025-02-15 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +27,989 | 1,827,623 | ||
| 2025-01-30 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2025-01-30 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2025-01-30 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +51,290 | 1,799,634 | ||
| 2025-01-16 | Pershing Edward CEO | Grant or award · 8% Unsecured Convertible Promissory Note | +0 | |||
| 2024-12-28 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2024-12-28 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +37,760 | 1,748,344 | ||
| 2024-12-02 | Bailey Webster Director | Grant or award · Stock Options (Right to Buy) | +775,082 | 775,082 | ||
| 2024-12-02 | Lacey John III Director | Grant or award · Stock Options (Right to Buy) | +775,082 | 775,082 | ||
| 2024-12-02 | WACHTER ERIC PHD CTO | Grant or award · Stock Options (Right to Buy) | +2,138,548 | 2,138,548 | ||
| 2024-12-02 | Raines Heather CFO | Grant or award · Stock Options (Right to Buy) | +4,197,890 | 4,197,890 | ||
| 2024-12-02 | Rodrigues Dominic President | Grant or award · Stock Options (Right to Buy) | +16,146,600 | 16,146,600 | ||
| 2024-12-02 | Pershing Edward CEO | Grant or award · Stock Options (Right to Buy) | +25,470,215 | 25,470,215 | ||
| 2024-11-29 | Pershing Edward CEO | Option exercise · 8% Unsecured Convertible Promissory Note | −0 | |||
| 2024-11-29 | Pershing Edward CEO | Option exercise · Series D-1 Convertible Preferred Stock | +18,880 | 1,710,584 |
Page 6 of 8 · 143 trades